Animal experiments not only serve as a basic process of the clinical transformation of new compounds,but also a key step in evaluating the safety and effectiveness of new drugs. Therefore, reasonable dose setting, animal model construction, and appropriate administration method are prerequisites to ensure reliable experimental data. However, in practice, scientific researchers have not formed a unified standard for the selection of animal experimental conditions,leading to deviations in efficacy evaluations and failure to effectively promote the transformation of new compounds into clinical practice. In view of this situation, the author takes the allogeneic tumor model constructed by 4T1 cells with the participation of cisplatin as an example to explore problems and possible solutions in the pharmacodynamic study of platinum compounds for the treatment of triple negative breast cancer. It is our hope that such findings will facilitate animal experiments that better serve clinical transformation.